Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva vs Chemotherapy in Advanced NSCLC (TITAN)
NCT00556322Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2006
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoints: Overall Survival up to 52 months and Probable Percentage of Participants Remaining Alive at 1 Year. Started Mar 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00556322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556322.